Advertisement
Advertisement
ADAP
Adaptimmune Therapeutics Plc - ADR
0.63
USD+0.0306
+5.11%
Dec 18, 13:30 UTC -5
Open
Adaptimmune Therapeutics Plc - ADR Profile
About
Info & Links
CEO
Adrian Rawcliffe
Headquarters
ABINGDON, X0 OX14 4RX, UNITED KINGDOM
Industry
Sector
Website
Auditor
KPMG LLP
Share holders
27
Employees
449
Adaptimmune Therapeutics Plc - ADR Statistics
Valuation Measures
Market Capitalization2
161.20M
Enterprise Value
94.33M
Enterprise Value/EBITDA(ttm)
-2.79
Price to Earnings Ratio(ttm)
--
Price to Sales(ttm)
0.85
Price to Book(mrq)
1.86
Price to Cash(ytd)
--
Profitability
Gross Margin(ttm)
100.00%
Operating Margin(ttm)
-25.43%
Profit Margin(ttm)
-5396.70%
Return on Equity(ttm)
-74.15%
Return on Invested Capital(ttm)
-276.48%
Return on Assets(ttm)
-15.09%
Income Statement
Revenue(ttm)
175.04M
Revenue Per Share(ttm)
--
Gross Profit(ttm)
175.04M
EBITDA(ttm)3
-33.84M
Net Income Available to Common(ttm)
-44.52M
Diluted EPS(ttm)
-0.22
Share Statistics
Beta (5Y Monthly)
2.18
52-Week Change
19.18%
S&P 500 52-Week Change
27.85%
S&P 500 Member
Yes
Stock Optionable
Yes
Total Shares Outstanding1
--
Dividend Yield
0.00%
Float4
224.05M
% Held by Insiders
12.44%
% Held by Institutions
31.37%
Balance Sheet
Total Cash(mrq)
186.09M
Total Cash Per Share(mrq)
--
Total Debt(mrq)
49.87M
Total Debt/Equity(mrq)
62.34%
Current Ratio(mrq)
3.85%
Quick Ratio(mrq)
3.82%
Book Value Per Share(mrq)
0.31
Cash Flow
Operating Cash Flow Per Share(ytd)
-0.15
Free Cash Flow(ytd)
-39.67M
Table Key
mrq = Most Recent Quarter
ttm = Trailing Twelve Months
ytd = Year To Date
Footnotes
Data provided by Zacks Investment Research or calculated by FXEmpire. All numbers are rounded to the closest decimal.
- 1 Total Shares outstanding is taken from the most recently filed quarterly or annual report.
- 2 Market Cap is calculated using total shares outstanding and the most recent share price.
- 3 EBITDA is calculated using methodology that may differ from that used by a company in its reporting.
- 4 The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.
Advertisement